moxifloxacin has been researched along with sitafloxacin in 19 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (sitafloxacin) | Trials (sitafloxacin) | Recent Studies (post-2010) (sitafloxacin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 16 | 0 | 3 |
| 3,157 | 552 | 1,690 | 185 | 22 | 85 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Baroni, M; Cecchetti, V; Cianchetta, G; Cruciani, G; Mannhold, R | 1 |
| Black, JA; Hanson, ND; Hong, SG; Hossain, A; Moland, ES; Thomson, KS; Wickman, PA | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Brisse, S; Fluit, AC; Heinz, HP; Milatovic, D; Schmitz, FJ; Verhoef, J | 1 |
| Finegold, S; Goldstein, E; Gorbach, SL; Harrell, L; Hecht, DW; Jacobus, NV; Jenkins, S; McDermott, LA; Pierson, C; Rihs, J; Ruthazer, R; Snydman, DR; Venezia, R | 1 |
| Chiba, K; Hagiwara, T; Hashimoto, K; Sugiyama, A; Takahashi, S; Takasuna, K | 1 |
| Chen, XY; Doi, N; Duan, HF; Fu, Y; Li, Q; Ma, Y | 1 |
| Sano, C; Sato, K; Shimizu, T; Tatano, Y; Tomioka, H; Yamabe, S | 1 |
| Berning, M; Krasz, S; Labenz, J; Miehlke, S; Morgner, A | 1 |
| Izumi, K; Mikamo, H; Ohki, E; Terada, M; Yamagishi, Y | 1 |
| Chen, X; Guo, X; Shi, G; Wang, H; Wang, S; Zhang, X | 1 |
| Malithong, A; Phiboonbanakit, D; Santiwatanakul, S; Srisangchan, P; Srisurat, N; Susaengrat, W; Tantisiriwat, W; Thamlikitkul, V; Thunyaharn, S; Tiengrim, S | 1 |
| Ang, TL; Song, M | 1 |
| Bodiyabadu, K; Bradshaw, CS; Danielewski, J; Durukan, D; Fairley, CK; Garland, SM; Jensen, JS; Machalek, DA; Mokany, E; Murray, GL; Tan, LY; Williamson, DA | 1 |
2 review(s) available for moxifloxacin and sitafloxacin
| Article | Year |
|---|---|
[Current value of quinolones in Helicobacter pylori therapy].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2011 |
Second and third line treatment options for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Moxifloxacin; Ofloxacin; Rifabutin; Rifamycins; Rifaximin; Salvage Therapy; Virulence Factors | 2014 |
17 other study(ies) available for moxifloxacin and sitafloxacin
| Article | Year |
|---|---|
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
Topics: Anti-Bacterial Agents; Enterococcus faecalis; Escherichia coli; Models, Molecular; Pseudomonas aeruginosa; Quantitative Structure-Activity Relationship; Quinolones; Staphylococcus aureus; Thermodynamics | 2004 |
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
Topics: Drug Resistance, Bacterial; Drug Resistance, Microbial; Fluoroquinolones; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Microbial Sensitivity Tests; Quinolones | 2007 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Staphylococcus aureus | 2000 |
In vitro activities of newer quinolones against bacteroides group organisms.
Topics: Anti-Infective Agents; Aza Compounds; Bacteroides; Bacteroides fragilis; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Indoles; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Quinolines; Quinolones | 2002 |
In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome.
Topics: Administration, Oral; Animals; Aza Compounds; Blood Pressure; Chloralose; Disease Models, Animal; Dogs; Electrocardiography; Female; Fluoroquinolones; Gatifloxacin; Halothane; Heart Block; Heart Rate; Infusions, Intravenous; Long QT Syndrome; Male; Moxifloxacin; Quinolines; Rabbits; Risk Assessment; Time Factors; Torsades de Pointes; Ventricular Function, Left | 2004 |
[Susceptibility test of the Mycobacterium avium complex to sixteen anti-infective agents].
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium; Quinolines | 2010 |
Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Humans; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium; Quinolines | 2011 |
Antimicrobial efficacies of several antibiotics against uterine cervicitis caused by Mycoplasma genitalium.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Polymerase Chain Reaction; Quinolines; Retrospective Studies; Uterine Cervicitis | 2012 |
Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Space; Fluoroquinolones; Intracellular Space; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Peritonitis; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Time Factors | 2012 |
Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Respiratory Tract Infections; Thailand; Urinary Tract Infections | 2012 |
Moxifloxacin and Sitafloxacin Treatment Failure in Mycoplasma genitalium Infection: Association with parC Mutation G248T (S83I) and Concurrent gyrA Mutations.
Topics: Anti-Bacterial Agents; Bacterial Proteins; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Mutation; Mycoplasma genitalium; Mycoplasma Infections; Treatment Failure | 2020 |